AdaptHealth vs Chemed
AHCO and CHE side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AHCO and CHE compare
Chemed is the larger company, worth 6.7 times as much as AdaptHealth ($7.2B against $1.1B).
AdaptHealth grew revenue faster over the last twelve months (20.7% versus 5.2% for Chemed).
Chemed keeps more of each dollar of sales as profit, with a net margin of 10.6% compared with −11.4% at AdaptHealth.
Chemed pays a dividend yielding 0.45%; AdaptHealth does not pay one.
Chemed scores higher on the StockData Score (17 against 7 for AdaptHealth), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AHCO | CHE |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $7.2B |
| Share price | $7.80 | $550.62 |
| Change, 1 year | −17.0% | 26.3% |
| Change, 5 years | −66.1% | 9.2% |
| Beta (5Y) | 0.72 | 0.35 |
| Employees | 11K | 16K |
| StockData Score | ||
| Total score | 7 | 17 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | – | 26.3× |
| P/S | 0.3× (better) | 2.7× |
| P/B | 0.9× (better) | 8.3× |
| EV/EBITDA | 24.4× | 16.8× (better) |
| P/FCF | 13.0× (better) | 24.3× |
| PEG | – | 7.47 |
| FCF yield | 7.7% (better) | 4.1% |
| Fair value | $19.99 | $524.63 |
| Margin of safety | 61.0% (better) | −5.0% |
| Growth | ||
| Revenue growth (TTM) | 20.7% (better) | 5.2% |
| Revenue growth, 5Y average | 25.2% (better) | 4.0% |
| Net income growth (TTM) | −595% | 1.3% (better) |
| EPS growth (TTM) | −638% | 10.5% (better) |
| EPS growth, 5Y average | – | −1.2% |
| Profitability | ||
| Gross margin | 15.7% | 33.5% (better) |
| Operating margin | −8.9% | 13.9% (better) |
| Net margin | −11.4% | 10.6% (better) |
| FCF margin | 2.3% | 11.1% (better) |
| Return on equity | −28.6% | 29.1% (better) |
| Return on invested capital | −7.9% | 27.4% (better) |
| Financial health | ||
| Debt / equity | 1.54 | 0.27 (better) |
| Net debt / EBITDA | 15.53 | 0.43 (better) |
| Interest coverage | – | 75.4× |
| Current ratio | 1.13 (better) | 1.11 |
| Altman Z-score | 0.53 | 9.86 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.45% |
| Payout ratio | – | 11.9% |
| Years of dividend growth | – | 16 |
| Dividend growth, 5Y average | – | 10.8% |
| Buyback yield | – | 7.3% |
| Shareholder yield | 0.00% | 7.8% (better) |
| Ownership | ||
| Held by institutions | 104% | 104% |
| Held by insiders | 14.7% | 1.4% |
| Insider net buying, 12 months | $49.1M (better) | −$9.5M |
| Short interest, % of float | 9.4% | 6.2% |
Go deeper
- AHCO stock overview
- AHCO income statement
- AHCO valuation and score
- CHE stock overview
- CHE income statement
- CHE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.